Michael K. Wong, M.D., Ph.D., FRCPC

Peer-Reviewed Articles

1. Rothrock AT, Truong LD, Shehabeldin A, Wong MKK, Cho WC, Nagarajan P, Vanderbeck K, Curry JL, Torres-Cabala CA, Prieto VG, Aung PP. Amyloid deposition with a granulomatous reaction in a resection specimen: A clue for a preexisting Merkel cell carcinoma. J Cutan Pathol 49(9):787-790, 2022. e-Pub 2022. PMID: 35734844.
2. Patel AB, Farooq S, Welborn M, Amaria RN, Chon SY, Diab A, Glitza Oliva IC, Huen AO, Li SQ, Nelson KC, Pacha O, Patel SP, Rapini RP, Tawbi HA, Wong MK, McQuade J, Davies MA, Haydu LE. Cutaneous adverse events in 155 patients with metastatic melanoma consecutively treated with anti-CTLA4 and anti-PD1 combination immunotherapy: Incidence, management, and clinical benefit. Cancer 128(5):975-983, 2022. e-Pub 2021. PMID: 34724197.
3. Kibbi N, Owen JL, Worley B, Wang JX, Harikumar V, Downing MB, Aasi SZ, Aung PP, Barker CA, Bolotin D, Bordeaux JS, Cartee TV, Chandra S, Cho NL, Choi JN, Chung KY, Cliby WA, Dorigo O, Eisen DB, Fujisawa Y, Golda N, Halfdanarson TR, Iavazzo C, Jiang SIB, Kanitakis J, Khan A, Kim JYS, Kuzel TM, Lawrence N, Leitao MM, MacLean AB, Maher IA, Mittal BB, Nehal KS, Ozog DM, Pettaway CA, Ross JS, Rossi AM, Servaes S, Solomon MJ, Thomas VD, Tolia M, Voelzke BB, Waldman A, Wong MK, Zhou Y, Arai N, Brackett A, Ibrahim SA, Kang BY, Poon E, Alam M. Evidence-Based Clinical Practice Guidelines for Extramammary Paget Disease. JAMA Oncol. e-Pub 2022. PMID: 35050310.
4. Amit M, Liu C, Mansour J, Gleber-Netto FO, Tam S, Baruch EN, Aashiq M, El-Naggar AK, Moreno AC, Rosenthal DI, Glisson BS, Ferrarotto R, Wong MK, Tsai K, Flores ER, Migden MR, Silverman DA, Li G, Khanna A, Goepfert RP, Nagarajan P, Weber RS, Myers JN, Gross ND. Elective neck dissection versus observation in patients with head and neck cutaneous squamous cell carcinoma. Cancer. e-Pub 2021. PMID: 34358340.
5. Andrews MC, Duong CPM, Gopalakrishnan V, Iebba V, Chen WS, Derosa L, Khan MAW, Cogdill AP, White MG, Wong MC, Ferrere G, Fluckiger A, Roberti MP, Opolon P, Alou MT, Yonekura S, Roh W, Spencer CN, Curbelo IF, Vence L, Reuben A, Johnson S, Arora R, Morad G, Lastrapes M, Baruch EN, Little L, Gumbs C, Cooper ZA, Prieto PA, Wani K, Lazar AJ, Tetzlaff MT, Hudgens CW, Callahan MK, Adamow M, Postow MA, Ariyan CE, Gaudreau PO, Nezi L, Raoult D, Mihalcioiu C, Elkrief A, Pezo RC, Haydu LE, Simon JM, Tawbi HA, McQuade J, Hwu P, Hwu WJ, Amaria RN, Burton EM, Woodman SE, Watowich S, Diab A, Patel SP, Glitza IC, Wong MK, Zhao L, Zhang J, Ajami NJ, Petrosino J, Jenq RR, Davies MA, Gershenwald JE, Futreal PA, Sharma P, Allison JP, Routy B, Zitvogel L, Wargo JA. Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade. Nat Med. e-Pub 2021. PMID: 34239137.
6. Tam S, Gajera M, Luo X, Glisson BS, Ferrarotto R, Johnson FM, Mott FE, Gillison ML, Lu C, Le X, Blumenschein GR, Wong MK, Rosenthal DI, Nagarajan P, El-Naggar AK, Midgen MR, Weber RS, Myers JN, Gross ND. Cytotoxic and Targeted Systemic Therapy in Patients with Advanced Cutaneous Squamous Cell Carcinoma in the Head and Neck. Head Neck 43(5):1592-1603, 2021. e-Pub 2021. PMID: 33522021.
7. Amit M, Liu C, Gleber-Netto FO, Kini S, Tam S, Benov A, Aashiq M, El-Naggar AK, Moreno AC, Rosenthal DI, Glisson BS, Ferrarotto R, Wong MK, Migden MR, Baruch EN, Li G, Khanna A, Goepfert RP, Nagarajan P, Weber RS, Myers JN, Gross ND. Inclusion of extranodal extension in the lymph node classification of cutaneous squamous cell carcinoma of the head and neck. Cancer 127(8):1238-1245, 2021. e-Pub 2020. PMID: 33320343.
8. Ogata D, Haydu LE, Glitza IC, Patel SP, Tawbi HA, McQuade JL, Diab A, Ekmekcioglu S, Wong MK, Davies MA, Amaria RN. The efficacy of anti-programmed cell death protein 1 therapy among patients with metastatic acral and metastatic mucosal melanoma. Cancer Med 10(7):2293-2299, 2021. e-Pub 2021. PMID: 33686688.
9. Amit M, Liu C, Netto Gleber FO, Kini S, Tam S, Benov A, Aashiq M, El-Naggar AK, Moreno AC, Rosenthal DI, Glisson BS, Ferrarotto R, Wong MK, Migden MR, Li G, Khanna A, Goepfert RP, Nagarajan P, Weber RS, Myers JN, Gross ND. Integrating depth of invasion in T classification improves the prognostic performance of the American Joint Committee on Cancer primary tumor staging system for cutaneous squamous cell carcinoma of the head and neck. Eur J Cancer 144:169-177, 2020. e-Pub 2020. PMID: 33352413.
10. Farah M, Reuben A, Spassova I, Yang RK, Kubat L, Nagarajan P, Ning J, Li W, Aung PP, Curry JL, Torres-Cabala CA, Hudgens CW, Ugurel S, Schadendorf D, Gumbs C, Little LD, Futreal A, Wistuba II, Prieto VG, Wang L, Wong MK, Wargo JA, Becker JC, Tetzlaff MT. T Cell repertoire in combination with T cell density predicts clinical outcomes in patients with Merkel cell carcinoma. J Invest Dermatol 140(11):2146-2156.e4, 2020. e-Pub 2020. PMID: 32304704.
11. Haydu LE, Lo SN, McQuade JL, Amaria RN, Wargo J, Ross MI, Cormier JN, Lucci A, Lee JE, Ferguson SD, Saw RPM, Spillane AJ, Shannon KF, Stretch JR, Hwu P, Patel SP, Diab A, Wong MKK, Glitza Oliva IC, Tawbi H, Carlino MS, Menzies AM, Long GV, Lazar AJ, Tetzlaff MT, Scolyer RA, Gershenwald JE, Thompson JF, Davies MA. Cumulative Incidence and Predictors of CNS Metastasis for Patients With American Joint Committee on Cancer 8th Edition Stage III Melanoma. J Clin Oncol 38(13):JCO1901508, 2020. e-Pub 2020. PMID: 31990608.
12. Lucci A, Hall CS, Patel SP, Narendran B, Bauldry JB, Royal RE, Karhade M, Upshaw JR, Wargo JA, Glitza IC, Wong MKK, Amaria RN, Tawbi HA, Diab A, Davies MA, Gershenwald JE, Lee JE, Hwu P, Ross MI. Circulating tumor cells and early relapse in node-positive melanoma. Clin Cancer Res 26(8):1886-1895, 2020. e-Pub 2020. PMID: 32015020.
13. Tam S, Yao CMKL, Amit M, Gajera M, Luo X, Treistman R, Khanna A, Aashiq M, Nagarajan P, Bell D, El-Naggar A, Migden M, Wong M, Glisson B, Ferrarotto R, Esmaeli B, Rosenthal D, Li G, Weber RS, Myers JN, Gross ND. Association of Immunosuppression With Outcomes of Patients With Cutaneous Squamous Cell Carcinoma of the Head and Neck. JAMA Otolaryngol Head Neck Surg 146(2):128-135, 2020. PMID: 31804658.
14. Owen JL, Kibbi N, Worley B, Kelm RC, Wang JV, Barker CA, Behshad R, Bichakjian CK, Bolotin D, Bordeaux JS, Bradshaw SH, Cartee TV, Chandra S, Cho NL, Choi JN, Council ML, Demirci H, Eisen DB, Esmaeli B, Golda N, Huang CC, Ibrahim SF, Jiang SB, Kim J, Kuzel TM, Lai SY, Lawrence N, Lee EH, Leitenberger JJ, Maher IA, Mann MW, Minkis K, Mittal BB, Nehal KS, Neuhaus IM, Ozog DM, Petersen B, Rotemberg V, Samant S, Samie FH, Servaes S, Shields CL, Shin TM, Sobanko JF, Somani AK, Stebbins WG, Thomas JR, Thomas VD, Tse DT, Waldman AH, Wong MK, Xu YG, Yu SS, Zeitouni NC, Ramsay T, Reynolds KA, Poon E, Alam M. Sebaceous carcinoma: evidence-based clinical practice guidelines. Lancet Oncol 20(12):e699-e714, 2019. PMID: 31797796.
15. Schvartsman G, Ma J, Bassett RL, Haydu LE, Amaria RN, Hwu P, Wong MK, Hwu WJ, Diab A, Patel SP, Davies MA, Hamerschlak N, Tawbi HA, Glitza Oliva IC. Incidence, patterns of progression, and outcomes of preexisting and newly discovered brain metastases during treatment with anti-PD-1 in patients with metastatic melanoma. Cancer 125(23):4193-4202, 2019. e-Pub 2019. PMID: 31398264.
16. Aung PP, Parra ER, Barua S, Sui D, Ning J, Mino B, Ledesma DA, Curry JL, Nagarajan P, Torres Cabala CA, Efstathiou E, Hoang A, Wong MKK, Wargo JA, Lazar AJ, Rao A, Prieto VG, Wistuba II, Tetzlaff MT. B7-H3 expression in Merkel cell carcinoma-associated endothelial cells correlates with locally aggressive primary tumor features and increased vascular density. Clinical Cancer Research 25(11):3455-3467, 2019. e-Pub 2019. PMID: 30808776.
17. Abdel-Wahab N, Safa H, Abudayyeh A, Johnson DH, Trinh VA, Zobniw CM, Lin H, Wong MK, Abdelrahim M, Gaber AO, Suarez-Almazor ME, Diab A. Corrections to: Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature. J Immunother Cancer 7(1):158, 2019. e-Pub 2019. PMID: 31234936.
18. Abdel-Wahab N, Safa H, Abudayyeh A, Johnson DH, Trinh VA, Zobniw CM, Lin H, Wong MK, Abdelrahim M, Gaber AO, Suarez-Almazor ME, Diab A. Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature. J Immunother Cancer 7(1):106, 2019. e-Pub 2019. PMID: 30992053.
19. Johnson DH, Zobniw CM, Trinh VA, Ma J, Bassett RL, Abdel-Wahab N, Anderson J, Davis JE, Joseph J, Uemura M, Noman A, Abu-Sbeih H, Yee C, Amaria R, Patel S, Tawbi H, Glitza IC, Davies MA, Wong MK, Woodman S, Hwu WJ, Hwu P, Wang Y, Diab A. Correction to: Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis. J Immunother Cancer 7(1):107, 2019. e-Pub 2019. PMID: 30995944.
20. Fishman M, Dutcher JP, Clark JI, Alva A, Miletello GP, Curti B, Agarwal N, Hauke R, Mahoney KM, Moon H, Treisman J, Tykodi SS, Daniels G, Morse MA, Wong MKK, Kaufman H, Gregory N, McDermott DF. Overall survival by clinical risk category for high dose interleukin-2 (HD IL-2) treated patients with metastatic renal cell cancer (mRCC): data from the PROCLAIM(SM) registry. J Immunother Cancer 7(84), 2019. PMID: 30917871.
21. Harms PW, Harms KL, Moore PS, DeCaprio JA, Nghiem P, Wong MKK, Brownell I, International Workshop on Merkel Cell Carcinoma Research (IWMCC) Working Group. The biology and treatment of Merkel cell carcinoma: current understanding and research priorities. Nat Rev Clin Oncol 15(12):763-776, 2018. PMID: 30287935.
22. Amaria RN, Reddy SM, Tawbi HA, Davies MA, Ross MI, Glitza IC, Cormier JN, Lewis C, Hwu WJ, Hanna E, Diab A, Wong MK, Royal R, Gross N, Weber R, Lai SY, Ehlers R, Blando J, Milton DR, Woodman S, Kageyama R, Wells DK, Hwu P, Patel SP, Lucci A, Hessel A, Lee JE, Gershenwald J, Simpson L, Burton EM, Posada L, Haydu L, Wang L, Zhang S, Lazar AJ, Hudgens CW, Gopalakrishnan V, Reuben A, Andrews MC, Spencer CN, Prieto V, Sharma P, Allison J, Tetzlaff MT, Wargo JA. Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nature Medicine 24(12):1941-1942, 2018. PMID: 30361511.
23. Diao K, Bian SX, Routman DM, Yu C, Kim PE, Wagle NA, Wong MK, Zada G, Chang EL. Combination ipilimumab and radiosurgery for brain metastases: tumor, edema, and adverse radiation effects. J Neurosurg 129(6):1397-1406, 2018. PMID: 29303446.
24. Forget MA, Haymaker C, Hess KR, Meng YJ, Creasy C, Karpinets T, Fulbright OJ, Roszik J, Woodman SE, Kim YU, Sakellariou-Thompson D, Bhatta A, Wahl A, Flores E, Thorsen ST, Tavera RJ, Ramachandran R, Gonzalez AM, Toth CL, Wardell S, Mansaray R, Patel V, Carpio DJ, Vaughn C, Farinas CM, Velasquez PG, Hwu WJ, Patel SP, Davies MA, Diab A, Glitza IC, Tawbi H, Wong MK, Cain S, Ross MI, Lee JE, Gershenwald JE, Lucci A, Royal R, Cormier JN, Wargo JA, Radvanyi LG, Torres-Cabala CA, Beroukhim R, Hwu P, Amaria RN, Bernatchez C. Prospective Analysis of Adoptive TIL Therapy in Patients with Metastatic Melanoma: Response, Impact of Anti-CTLA4, and Biomarkers to Predict Clinical Outcome. Clin Cancer Res 24(18):4416-4428, 2018. e-Pub 2018. PMID: 29848573.
25. Diao K, Bian SX, Routman DM, Yu C, Ye JC, Wagle NA, Wong MK, Zada G, Chang EL. Stereotactic radiosurgery and ipilimumab for patients with melanoma brain metastases: clinical outcomes and toxicity. J Neurooncol 139(2):421-429, 2018. e-Pub 2018. PMID: 29696531.
26. Amaria RN, Prieto PA, Tetzlaff MT, Reuben A, Andrews MC, Ross MI, Glitza IC, Cormier J, Hwu WJ, Tawbi HA, Patel SP, Lee JE, Gershenwald JE, Spencer CN, Gopalakrishnan V, Bassett R, Simpson L, Mouton R, Hudgens CW, Zhao L, Zhu H, Cooper ZA, Wani K, Lazar A, Hwu P, Diab A, Wong MK, McQuade JL, Royal R, Lucci A, Burton EM, Reddy S, Sharma P, Allison J, Futreal PA, Woodman SE, Davies MA, Wargo JA. Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial. Lancet Oncol 19(2):181-193, 2018. e-Pub 2018. PMID: 29361468.
27. Curti B, Daniels GA, McDermott DF, Clark JI, Kaufman HL, Logan TF, Singh J, Kaur M, Luna TL, Gregory N, Morse MA, Wong MK, Dutcher JP. Improved survival and tumor control with Interleukin-2 is associated with the development of immune-related adverse events: data from the PROCLAIMSM registry. J Immunother Cancer 5(1):102, 2017. e-Pub 2017. PMID: 29254506.
28. Johnson MM, Leachman SA, Aspinwall LG, Cranmer LD, Curiel-Lewandrowski C, Sondak VK, Stemwedel CE, Swetter SM, Vetto J, Bowles T, Dellavalle RP, Geskin LJ, Grossman D, Grossmann KF, Hawkes JE, Jeter JM, Kim CC, Kirkwood JM, Mangold AR, Meyskens F, Ming ME, Nelson KC, Piepkorn M, Pollack BP, Robinson JK, Sober AJ, Trotter S, Venna SS, Agarwala S, Alani R, Averbook B, Bar A, Becevic M, Box N, E Carson W, Cassidy PB, Chen SC, Chu EY, Ellis DL, Ferris LK, Fisher DE, Kendra K, Lawson DH, Leming PD, Margolin KA, Markovic S, Martini MC, Miller D, Sahni D, Sharfman WH, Stein J, Stratigos AJ, Tarhini A, Taylor MH, Wisco OJ, Wong MK. Skin cancer screening: recommendations for data-driven screening guidelines and a review of the US Preventive Services Task Force controversy. Melanoma Manag 4(1):13-37, 2017. e-Pub 2017. PMID: 28758010.
29. Altieri L, Wong MK, Peng DH, Cockburn M. Mucosal melanomas in the racially diverse population of California. J Am Acad Dermatol 76(2):250-257, 2017. e-Pub 2016. PMID: 27742175.
30. Clark JI, Wong MK, Kaufman HL, Daniels GA, Morse MA, McDermott DF, Agarwala SS, Lewis LD, Stewart JH, Vaishampayan U, Curti B, Gonzalez R, Lutzky J, Rudraptna V, Cranmer LD, Jeter JM, Hauke RJ, Miletello G, Milhem MM, Amin A, Richart JM, Fishman M, Hallmeyer S, Patel SP, Van Veldhuizen P, Agarwal N, Taback B, Treisman JS, Ernstoff MS, Perritt JC, Hua H, Rao TB, Dutcher JP, Aung S. Impact of Sequencing Targeted Therapies With High-dose Interleukin-2 Immunotherapy: An Analysis of Outcome and Survival of Patients With Metastatic Renal Cell Carcinoma From an On-going Observational IL-2 Clinical Trial: PROCLAIM(SM). Clin Genitourin Cancer 15(1):31-41.e4, 2017. e-Pub 2016. PMID: 27916626.
31. Woodham AW, Yan L, Skeate JG, van der Veen D, Brand HH, Wong MK, Da Silva DM, Kast WM. T cell ignorance is bliss: T cells are not tolerized by Langerhans cells presenting human papillomavirus antigens in the absence of costimulation. Papillomavirus Res 2:21-30, 2016. PMID: 27182559.
32. Alva A, Daniels GA, Wong MK, Kaufman HL, Morse MA, McDermott DF, Clark JI, Agarwala SS, Miletello G, Logan TF, Hauke RJ, Curti B, Kirkwood JM, Gonzalez R, Amin A, Fishman M, Agarwal N, Lowder JN, Hua H, Aung S, Dutcher JP. Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma. Cancer Immunol Immunother 65(12):1533-1544, 2016. e-Pub 2016. PMID: 27714434.
33. Bian SX, Routman D, Liu J, Yang D, Groshen S, Zada G, Trakul N, Wong MK, Yu C, Chang EL. Prognostic factors for melanoma brain metastases treated with stereotactic radiosurgery. J Neurosurg 125(Suppl 1):31-39, 2016. PMID: 27903181.
34. Ross JS, Wang K, Chmielecki J, Gay L, Johnson A, Chudnovsky J, Yelensky R, Lipson D, Ali SM, Elvin JA, Vergilio JA, Roels S, Miller VA, Nakamura BN, Gray A, Wong MK, Stephens PJ. The distribution of BRAF gene fusions in solid tumors and response to targeted therapy. Int J Cancer 138(4):881-90, 2016. e-Pub 2015. PMID: 26314551.
35. Da Silva DM, Woodham AW, Rijkee LK, Skeate JG, Taylor JR, Koopman ME, Brand HE, Wong MK, McKee GM, Salazar AM, Kast WM. Human papillomavirus-exposed Langerhans cells are activated by stabilized Poly-I:C. Papillomavirus Res 1:12-21, 2015. PMID: 26665182.
36. Wong MK, Jonasch E, Pal SK, Signorovitch JE, Lin PL, Wang X, Liu Z, Culver K, Scott JA, George DJ, Vogelzang NJ. Prognostic factors for survival following initiation of second-line treatment with everolimus for metastatic renal cell carcinoma: evidence from a nationwide sample of clinical practice in the United States. Expert Opin Pharmacother 16(6):805-19, 2015. e-Pub 2015. PMID: 25766864.
37. Ahmad S, Hewett PW, Fujisawa T, Sissaoui S, Cai M, Gueron G, Al-Ani B, Cudmore M, Ahmed SF, Wong MK, Wegiel B, Otterbein LE, Vítek L, Ramma W, Wang K, Ahmed A. Carbon monoxide inhibits sprouting angiogenesis and vascular endothelial growth factor receptor-2 phosphorylation. Thromb Haemost 113(2):329-37, 2015. e-Pub 2014. PMID: 25354586.
38. McDermott DF, Cheng SC, Signoretti S, Margolin KA, Clark JI, Sosman JA, Dutcher JP, Logan TF, Curti BD, Ernstoff MS, Appleman L, Wong MK, Khushalani NI, Oleksowicz L, Vaishampayan UN, Mier JW, Panka DJ, Bhatt RS, Bailey AS, Leibovich BC, Kwon ED, Kabbinavar FF, Belldegrun AS, Figlin RA, Pantuck AJ, Regan MM, Atkins MB. The high-dose aldesleukin "select" trial: a trial to prospectively validate predictive models of response to treatment in patients with metastatic renal cell carcinoma. Clin Cancer Res 21(3):561-8, 2015. e-Pub 2014. PMID: 25424850.
39. Signorovitch JE, Vogelzang NJ, Pal SK, Lin PL, George DJ, Wong MK, Liu Z, Wang X, Culver K, Scott JA, Jonasch E. Comparative effectiveness of second-line targeted therapies for metastatic renal cell carcinoma: synthesis of findings from two multi-practice chart reviews in the United States. Curr Med Res Opin 30(11):2343-53, 2014. e-Pub 2014. PMID: 25105304.
40. Lam ET, Wong MK, Agarwal N, Redman BG, Logan T, Gao D, Flaig TW, Lewis K, Poust J, Monk P, Jarkowski A, Sendilnathan A, Bolden M, Kuzel TM, Olencki T. Retrospective analysis of the safety and efficacy of high-dose interleukin-2 after prior tyrosine kinase inhibitor therapy in patients with advanced renal cell carcinoma. J Immunother 37(7):360-5, 2014. PMID: 25075565.
41. Carvajal RD, Wong MK, Thompson JA, Gordon MS, Lewis KD, Pavlick AC, Wolchok JD, Rojas PB, Schwartz JD, Bedikian AY. A phase 2 randomised study of ramucirumab (IMC-1121B) with or without dacarbazine in patients with metastatic melanoma. Eur J Cancer 50(12):2099-107, 2014. e-Pub 2014. PMID: 24930625.
42. Liu Y, Fang J, Kim YJ, Wong MK, Wang P. Codelivery of doxorubicin and paclitaxel by cross-linked multilamellar liposome enables synergistic antitumor activity. Mol Pharm 11(5):1651-61, 2014. e-Pub 2014. PMID: 24673622.
43. Woodham AW, Raff AB, Raff LM, Da Silva DM, Yan L, Skeate JG, Wong MK, Lin YG, Kast WM. Inhibition of Langerhans cell maturation by human papillomavirus type 16: a novel role for the annexin A2 heterotetramer in immune suppression. J Immunol 192(10):4748-57, 2014. e-Pub 2014. PMID: 24719459.
44. Wong MK, Yang H, Signorovitch JE, Wang X, Liu Z, Liu NS, Qi CZ, George DJ. Comparative outcomes of everolimus, temsirolimus and sorafenib as second targeted therapies for metastatic renal cell carcinoma: a US medical record review. Curr Med Res Opin 30(4):537-45, 2014. e-Pub 2013. PMID: 24329572.
45. Da Silva DM, Movius CA, Raff AB, Brand HE, Skeate JG, Wong MK, Kast WM. Suppression of Langerhans cell activation is conserved amongst human papillomavirus α and β genotypes, but not a µ genotype. Virology 452-453:279-86, 2014. e-Pub 2014. PMID: 24606705.
46. Kaufman HL, Wong MK, Daniels GA, McDermott DF, Aung S, Lowder JN, Morse MA. The Use of Registries to Improve Cancer Treatment: A National Database for Patients Treated with Interleukin-2 (IL-2). J Pers Med 4(1):52-64, 2014. e-Pub 2014. PMID: 25562142.
47. Wong MK, Kaufman HL, Daniels GA, McDermott DF, Aung S, Lowder JN, Morse MA. Implementation of an Interleukin-2 National Registry: an opportunity to improve cancer outcomes. J Immunother Cancer 2:20, 2014. e-Pub 2014. PMID: 25031835.
48. Liu Y, Fang J, Joo KI, Wong MK, Wang P. Codelivery of chemotherapeutics via crosslinked multilamellar liposomal vesicles to overcome multidrug resistance in tumor. PLoS One 9(10):e110611, 2014. e-Pub 2014. PMID: 25330237.
49. Hu JS, Skeate JG, Kast WM, Wong MK. Immunotherapy in sarcoma: a brief review. Sarcoma Res Int 1:1-8, 2014.
50. Dorff TB, Wong MK. Weighing the evidence for immune therapy and targeted therapy in renal cancer and melanoma. Oncology (Williston Park) 27(7):691-2, 694, 2013. PMID: 23977764.
51. Wong MK, Wang X, Chulikavit MJ, Liu Z. Review of US Comparative Economic Evidence for Treatment of Metastatic Renal Cell Carcinoma after Failure of First-Line VEGF Inhibitor Therapy. Am Health Drug Benefits 6(5):275-86, 2013. PMID: 24991363.
52. Joo KI, Xiao L, Liu S, Liu Y, Lee CL, Conti PS, Wong MK, Li Z, Wang P. Crosslinked multilamellar liposomes for controlled delivery of anticancer drugs. Biomaterials 34(12):3098-109, 2013. e-Pub 2013. PMID: 23375392.
53. Wong MK, Jarkowski A. Ipilimumab: Unique Responses, Toxicities, and Recommendations for the Use of the First Anti–CTLA-4 Therapy in Patients with Melanoma. J Hematol Oncol Pharm 3(1):16-23, 2013.
54. Roosta N, Black DS, Wong MK, Woodley DT. Assessing hairdressers' knowledge of scalp and neck melanoma and their willingness to detect lesions and make referrals to dermatologists. J Am Acad Dermatol 68(1):183-5, 2013. PMID: 23244380.
55. Liu Y, Ji M, Wong MK, Joo KI, Wang P. Enhanced therapeutic efficacy of iRGD-conjugated crosslinked multilayer liposomes for drug delivery. Biomed Res Int 2013:378380, 2013. e-Pub 2013. PMID: 23691500.
56. Rosen LS, Hurwitz HI, Wong MK, Goldman J, Mendelson DS, Figg WD, Spencer S, Adams BJ, Alvarez D, Seon BK, Theuer CP, Leigh BR, Gordon MS. A phase I first-in-human study of TRC105 (Anti-Endoglin Antibody) in patients with advanced cancer. Clin Cancer Res 18(17):4820-9, 2012. e-Pub 2012. PMID: 22767667.
57. Roosta N, Wong MK, Woodley DT, Norris Comprehensive Cancer Center Melanoma Working Group. Utilizing hairdressers for early detection of head and neck melanoma: an untapped resource. J Am Acad Dermatol 66(4):687-8, 2012. PMID: 22421114.
58. Wong MK, Mohamed AF, Hauber AB, Yang JC, Liu Z, Rogerio J, Garay CA. Patients rank toxicity against progression free survival in second-line treatment of advanced renal cell carcinoma. J Med Econ 15(6):1139-48, 2012. e-Pub 2012. PMID: 22808923.
59. Jarkowski A, Glode AE, Spangenthal EJ, Wong MK. Heart failure caused by molecularly targeted therapies for cancer. Pharmacotherapy 31(1):62-75, 2011. PMID: 21182360.
60. Jarkowski A, Miller A, Heckle TA, Blustein L, Wong MK.. The risk of neurotoxicity with concomitant use of aprepitant and ifosfamide. J Hematol Oncol Pharm 1(2):16-21, 2011.
61. Bhattacharya A, Tang L, Li Y, Geng F, Paonessa JD, Chen SC, Wong MK, Zhang Y. Inhibition of bladder cancer development by allyl isothiocyanate. Carcinogenesis 31(2):281-6, 2010. e-Pub 2009. PMID: 19955395.
62. Agarwala SS, Gray RJ, Wong MK. Duration of high-dose interferon alpha-2b regimen for resected high-risk melanoma. J Clin Oncol 27(25):e82-3; author reply e84, 2009. e-Pub 2009. PMID: 19635995.
63. Wong MK, Jarkowski A. Response to sorafenib after sunitinib-induced acute heart failure in a patient with metastatic renal cell carcinoma: case report and review of the literature. Pharmacotherapy 29(4):473-8, 2009. PMID: 19323623.
64. Coit DG, Andtbacka R, Bichakjian CK, Dilawari RA, Dimaio D, Guild V, Halpern AC, Hodi FS, Kashani-Sabet M, Lange JR, Lind A, Martin L, Martini MC, Pruitt SK, Ross MI, Sener SF, Swetter SM, Tanabe KK, Thompson JA, Trisal V, Urist MM, Weber J, Wong MK, NCCN Melanoma Panel. Melanoma. J Natl Compr Canc Netw 7(3):250-75, 2009. PMID: 19401060.
65. Crawford J, Armitage J, Balducci L, Bennett C, Blayney DW, Cataland SR, Dale DC, Demetri GD, Erba HP, Foran J, Freifeld AG, Goemann M, Heaney ML, Htoy S, Hudock S, Kloth DD, Kuter DJ, Lyman GH, Michaud LB, Miyata SC, Tallman MS, Vadhan-Raj S, Westervelt P, Wong MK, National Comprehensive Cancer Network. Myeloid growth factors. J Natl Compr Canc Netw 7(1):64-83, 2009. PMID: 19176207.
66. Chen SC, Henry DO, Hicks DG, Reczek PR, Wong MK. Intravesical administration of plasminogen activator inhibitor type-1 inhibits in vivo bladder tumor invasion and progression. J Urol 181(1):336-42, 2009. e-Pub 2008. PMID: 19010488.
67. Jarkowski A, Wong MK. A re-assessment of the safety and efficacy of Interleukin-2 for the treatment of renal cell carcinoma. Clinical Medicine: Therapeutics 1:527-40, 2009.
68. Wong MK. The current role of immunotherapy for renal cell carcinoma in the era of targeted therapeutics. Curr Oncol Rep 10(3):259-63, 2008. PMID: 18765157.
69. Chen SC, Henry DO, Reczek PR, Wong MK. Plasminogen activator inhibitor-1 inhibits prostate tumor growth through endothelial apoptosis. Mol Cancer Ther 7(5):1227-36, 2008. PMID: 18483310.
70. Rigual NR, Popat SR, Jayaprakash V, Jaggernauth W, Wong MK. Cutaneous head and neck melanoma: the old and the new. Expert Rev Anticancer Ther 8(3):403-12, 2008. PMID: 18366288.
71. Chapman TN, Sharma S, Zhang S, Wong MK, Kim HL. Laparoscopic lymph node dissection in clinically node-negative patients undergoing laparoscopic nephrectomy for renal carcinoma. Urology 71(2):287-91, 2008. PMID: 18308105.
72. Fang X, Rodabaugh K, Penetrante R, Wong MK, Wagner T, Sait S, Mhawech-Fauceglia P. Desmoplastic small round cell tumor (DSRCT) with ovarian involvement in 2 young women. Appl Immunohistochem Mol Morphol 16(1):94-9, 2008. PMID: 18091312.
73. Moschos SJ, Odoux C, Land SR, Agarwala S, Friedland D, Volker KM, Sidor C, Wong MK, Kirkwood JM. Endostatin plus interferon-alpha2b therapy for metastatic melanoma: a novel combination of antiangiogenic and immunomodulatory agents. Melanoma Res 17(3):193-200, 2007. PMID: 17505265.
74. Biermann JS, Adkins D, Benjamin R, Brigman B, Chow W, Conrad EU, Frassica D, Frassica FJ, George S, Healey JH, Heck R, Letson GD, Mayerson J, McGarry SV, O'Donnell RJ, Patt J, Randall RL, Santana V, Satcher RL, Schmidt RG, Siegel HJ, Wong MK, Yasko AW, National Comprehensive Cancer Network. Bone cancer. J Natl Compr Canc Netw 5(4):420-37, 2007. PMID: 17442233.
75. Crawford J, Althaus B, Armitage J, Balducci L, Bennett C, Blayney DW, Cataland SR, Dale DC, Demetri GD, Erba HP, Foran J, Freifeld AG, Heaney ML, Htoy S, Kloth DD, Lyman GH, Messersmith WA, Michaud LB, Miyata SC, Robbins A, Tallman MS, Vadhan-Raj S, Westervelt P, Wong MK, National Comprehensive Cancer Network (NCCN). Myeloid growth factors. Clinical practice guidelines in oncology. J Natl Compr Canc Netw 5(2):188-202, 2007. PMID: 17335688.
76. Park HK, Zhang S, Wong MK, Kim HL. Clinical presentation of epithelioid angiomyolipoma. Int J Urol 14(1):21-5, 2007. PMID: 17199855.
77. Chung I, Wong MK, Flynn G, Yu WD, Johnson CS, Trump DL. Differential antiproliferative effects of calcitriol on tumor-derived and matrigel-derived endothelial cells. Cancer Res 66(17):8565-73, 2006. PMID: 16951169.
78. Ohta A, Gorelik E, Prasad SJ, Ronchese F, Lukashev D, Wong MK, Huang X, Caldwell S, Liu K, Smith P, Chen JF, Jackson EK, Apasov S, Abrams S, Sitkovsky M. A2A adenosine receptor protects tumors from antitumor T cells. Proc Natl Acad Sci U S A 103(35):13132-7, 2006. e-Pub 2006. PMID: 16916931.
79. Ravi V, Wong MK. Strategies and methodologies for identifying molecular targets in sarcomas and other tumors. Curr Treat Options Oncol 6(6):487-97, 2005. PMID: 16242053.
80. Matin K, Jacobs SA, Richards T, Wong MK, Earle M, Evans T, Troetschel M, Ferri W, Friedland D, Pinkerton R, Volkin R, Wieand S, Ramanathan RK. A phase I/II study of trimetrexate and capecitabine in patients with advanced refractory colorectal cancer. Am J Clin Oncol 28(5):439-44, 2005. PMID: 16199980.
81. Khoury T, Balos L, McGrath B, Wong MK, Cheney RT, Tan D. Malignant glomus tumor: a case report and review of literature, focusing on its clinicopathologic features and immunohistochemical profile. Am J Dermatopathol 27(5):428-31, 2005. PMID: 16148414.
82. Crawford J, Althaus B, Armitage J, Blayney DW, Cataland S, Dale DC, Demetri GD, Foran J, Heaney ML, Htoy S, Kloth DD, Lyman GH, Michaud L, Motl S, Vadhan-Raj S, Wong MK, National Comprehensive Cancer Network. Myeloid growth factors clinical practice guidelines in oncology. J Natl Compr Canc Netw 3(4):540-55, 2005. PMID: 16038645.
83. Ramanathan RK, Trump DL, Eiseman JL, Belani CP, Agarwala SS, Zuhowski EG, Lan J, Potter DM, Ivy SP, Ramalingam S, Brufsky AM, Wong MK, Tutchko S, Egorin MJ. Phase I pharmacokinetic-pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin (17AAG, NSC 330507), a novel inhibitor of heat shock protein 90, in patients with refractory advanced cancers. Clin Cancer Res 11(9):3385-91, 2005. PMID: 15867239.
84. Weller GE, Wong MK, Modzelewski RA, Lu E, Klibanov AL, Wagner WR, Villanueva FS. Ultrasonic imaging of tumor angiogenesis using contrast microbubbles targeted via the tumor-binding peptide arginine-arginine-leucine. Cancer Res 65(2):533-9, 2005. PMID: 15695396.
85. Zamboni WC, Jung LL, Egorin MJ, Potter DM, Friedland DM, Belani CP, Agarwala SS, Wong MK, Fakih M, Trump DL, Jin R, Strychor S, Vozniak M, Troetschel M, Ramanathan RK. Phase I and pharmacologic study of intermittently administered 9-nitrocamptothecin in patients with advanced solid tumors. Clin Cancer Res 10(15):5058-64, 2004. PMID: 15297407.
86. Ramanathan RK, Hwang JJ, Zamboni WC, Sinicrope FA, Safran H, Wong MK, Earle M, Brufsky A, Evans T, Troetschel M, Walko C, Day R, Chen HX, Finkelstein S. Low overexpression of HER-2/neu in advanced colorectal cancer limits the usefulness of trastuzumab (Herceptin) and irinotecan as therapy. A phase II trial. Cancer Invest 22(6):858-65, 2004. PMID: 15641483.
87. Li M, Huang X, Zhu Z, Zhao Q, Wong MK, Gorelik E. The therapeutic efficacy of angiostatin against weakly- and highly-immunogenic 3LL tumors. In Vivo 16(6):577-82, 2002. PMID: 12494903.
88. Huang X, Wong MK, Yi H, Watkins S, Laird AD, Wolf SF, Gorelik E. Combined therapy of local and metastatic 4T1 breast tumor in mice using SU6668, an inhibitor of angiogenic receptor tyrosine kinases, and the immunostimulator B7.2-IgG fusion protein. Cancer Res 62(20):5727-35, 2002. PMID: 12384531.
89. Odoux C, Albers A, Amoscato AA, Lotze MT, Wong MK. TRAIL, FasL and a blocking anti-DR5 antibody augment paclitaxel-induced apoptosis in human non-small-cell lung cancer. Int J Cancer 97(4):458-65, 2002. PMID: 11802207.
90. Li M, Huang X, Zhu Z, Wong MK, Watkins S, Zhao Q, Herberman R, Gorelik E. Immune response against 3LL Lewis lung carcinoma potentiates the therapeutic efficacy of endostatin. J Immunother 24(6):472-81, 2001. PMID: 11759070.
91. McMahon GA, Petitclerc E, Stefansson S, Smith E, Wong MK, Westrick RJ, Ginsburg D, Brooks PC, Lawrence DA. Plasminogen activator inhibitor-1 regulates tumor growth and angiogenesis. J Biol Chem 276(36):33964-8, 2001. e-Pub 2001. PMID: 11441025.
92. Stefansson S, Petitclerc E, Wong MK, McMahon GA, Brooks PC, Lawrence DA. Inhibition of angiogenesis in vivo by plasminogen activator inhibitor-1. J Biol Chem 276(11):8135-41, 2001. e-Pub 2000. PMID: 11083866.
93. Midha R, Shoichet MS, Dalton PD, Cao X, Munro CA, Noble J, Wong MK. Tissue engineered alternatives to nerve transplantation for repair of peripheral nervous system injuries. Transplant Proc 33(1-2):612-5, 2001. PMID: 11266983.
94. Huang X, Wong MK, Zhao Q, Zhu Z, Wang KZ, Huang N, Ye C, Gorelik E, Li M. Soluble recombinant endostatin purified from Escherichia coli: antiangiogenic activity and antitumor effect. Cancer Res 61(2):478-81, 2001. PMID: 11212235.
95. Brown CK, Modzelewski RA, Johnson CS, Wong MK. A novel approach for the identification of unique tumor vasculature binding peptides using an E. coli peptide display library. Ann Surg Oncol 7(10):743-9, 2000. PMID: 11129422.
96. Wexler EJ, Gravallese EM, Czerniak PM, Devenny JJ, Longtine J, Wong MK, Slee AM, Kerr JS. Tumor biology: use of tiled images in conjunction with measurements of cellular proliferation and death in response to drug treatments. Clin Cancer Res 6(8):3361-70, 2000. PMID: 10955824.
97. Yepes M, Sandkvist M, Wong MK, Coleman TA, Smith E, Cohan SL, Lawrence DA. Neuroserpin reduces cerebral infarct volume and protects neurons from ischemia-induced apoptosis. Blood 96(2):569-76, 2000. PMID: 10887120.
98. Wong MK, Prudovsky I, Vary C, Booth C, Liaw L, Mousa S, Small D, Maciag T. A non-transmembrane form of Jagged-1 regulates the formation of matrix-dependent chord-like structures. Biochem Biophys Res Commun 268(3):853-9, 2000. PMID: 10679295.
99. Wong MK, Bjarnason GA, Hrushesky WJ, Webster P, Morava-Protzner I, Towers M. Steroid-responsive interstitial lung disease in patients receiving 2'-deoxy-5-fluorouridine-infusion chemotherapy. A report of three cases. Cancer 75(10):2558-64, 1995. PMID: 7736401.
100. Gottlieb AI, Langille BL, Wong MK, Kim DW. Structure and function of the endothelial cytoskeleton. Lab Invest 65(2):123-37, 1991. PMID: 1881118.
101. Wong MK, Gotlieb AI. Endothelial monolayer integrity. Perturbation of F-actin filaments and the dense peripheral band-vinculin network. Arteriosclerosis 10(1):76-84, 1990. PMID: 2136994.
102. Kim DW, Langille BL, Wong MK, Gotlieb AI. Patterns of endothelial microfilament distribution in the rabbit aorta in situ. Circ Res 64(1):21-31, 1989. PMID: 2909301.
103. Wong MK, Gotlieb AI. The reorganization of microfilaments, centrosomes, and microtubules during in vitro small wound reendothelialization. J Cell Biol 107(5):1777-83, 1988. PMID: 3182937.
104. Gotlieb AI, Wong MK. Atherosclerosis: activation of the injured vessel wall. Cardiovasc Clin 18(2):3-21, 1988. PMID: 3275417.
105. Gotlieb AI, Wong MK, Boden P, Fone AC. The role of the cytoskeleton in endothelial repair. Scanning Microsc 1(4):1715-26, 1987. PMID: 3433059.
106. Koo EW, Hayes MA, Wong MK, Gotlieb AI. Aflatoxin B1 and acetaminophen induce different cytoskeletal responses during prelethal hepatocyte injury. Exp Mol Pathol 47(1):37-47, 1987. PMID: 3111878.
107. Wong MK, Gotlieb AI. Endothelial cell monolayer integrity. I. Characterization of dense peripheral band of microfilaments. Arteriosclerosis 6(2):212-9, 1986. PMID: 3954675.
108. Wong MK, Gotlieb AI. Control of reendothelialization: the importance of endothelial microfilaments, microtubules and centrosomes in endothelial locomotion. Surv Synth Pathol Res 4(5-6):341-56, 1985. PMID: 3837928.
109. Wong MK, Gotlieb AI. In vitro reendothelialization of a single-cell wound. Role of microfilament bundles in rapid lamellipodia-mediated wound closure. Lab Invest 51(1):75-81, 1984. PMID: 6376946.
110. Gotlieb AI, Spector W, Wong MK, Lacey C. In vitro reendothelialization. Microfilament bundle reorganization in migrating porcine endothelial cells. Arteriosclerosis 4(2):91-6, 1984. PMID: 6367729.
111. Gotlieb AI, Wong MK. The effect of platelet poor plasma serum on endothelial cell spreading. Artery 9(1):59-68, 1981. PMID: 7247738.

Invited Articles

1. Agarwala,S, Wong MK. Antiangiogenic Tyrosine Kinase Inhibitors and Their Diverse Spectra of Inhibitory Activity: Implications for Personalized Therapy in Renal Cell Carcinoma. Personalized Medicine in Oncology 2(5):243-53, 2013.
2. Wong MK. Melanoma Biology. Community Oncology 5(3):6-14, 2008.
3. Wong MK. Death by Design: a primer on apoptosis and cancer. Current Oncology 3:18-21, 1996.
4. Wong MK. The promise of antitumor angiogenesis therapy. Current Oncology 3:179-84, 1996.

Manuals, Teaching Aids, Other Teaching Publications

1. Falchook GS, Woodman S, Wong MK. In Handbook of Targeted Cancer Therapy and Immunotherapy 2nd Edition Karp DD and Falchook GS eds., Wolter Kluwer: New York, 2019.

Editorials

1. Wong MK. Expert Point of View: Dual BRAF and MEK Inhibition Is Active in Advanced Melanoma. The ASCO Post 3(6), 2012.
2. Wong MK. Selecting Appropriate Pharmacologic Treatment in Renal Cell Carcinoma: Considerations for Managed Care Decision Makers. Managed Care Oncology - Drug Therapy Reviews, 2012.

Abstracts

1. Wong MK, Kelly CM, Burgess MA, Lewis K, Grewal JS, Olszanski AJ, McGreivy J, Rothbaum W, Qamoos H, DeCaprio JA.. KRT‑232, a first-in-class, murine double minute 2 inhibitor (MDM2i), for TP53 wild-type (p53WT) Merkel cell carcinoma (MCC) after anti–PD‑1/L1 immunotherapy. ASCO, 2020.
2. McKean MA, Haydu LE, Ma J, Bassett RL, Hwu W, Patel SP, Diab A, Glitza IC, Tawbi HA, Wong MK, McQuade JL, Hwu P, Davies MA, Amaria RN. Prognostic factors for overall survival (OS) in metastatic melanoma (MM) patients (pts) treated with immune checkpoint inhibitors: A single institution study of 696 pts. ASCO, 2020.
3. Colen RR, Ologun GO, Zinn P, Murat AK, Arora R, Burton EM, Glitza IC, Tawbi HA, Patel SP, Diab A, Wong MK, McQuade JL, Ross MI, Ahmed S, Elshafeey N, Gershenwald JE, Davies MA, Tetzlaff MT, Amaria RN, Wargo JA. Radiomic signatures to predict response to targeted therapy and immune checkpoint blockade in melanoma patients (pts) on neoadjuvant therapy. ASCO, 2020.
4. Keung E, Burton EM, Amaria RN, Glitza IC, Patel SP, Diab A, Yee C, Wong MK, Hwu W, Hwu P, Woodman SE, Tetzlaff MT, Milton D, Perez K, Davies MA, Rai K, Wargo JA, Tawbi HA. A phase II study of oral azacitidine (CC-486) in combination with pembrolizumab (PEMBRO) in patients with metastatic melanoma (MM). ASCO, 2020.
5. Diab A, Tykodi S, Curti B, Cho D, Wong MK, Puzanov I. Immune monitoring after NKTR-214 plus nivolumab (PIVOT-02) in previously untreated patients with metastatic Stage IV melanoma. J Transl Med 17, 2019.
6. Diab A, Tannir NM, Bernatchez C, Haymaker CL, Bentebibel SE, Curt, BD, Wong MK, Gergel I, Tagliaferri MA, Zalevsky J, Hoch U. A phase 1/2 study of a novel IL-2 cytokine, NKTR-214, and nivolumab in patients with select locally advanced or metastatic solid tumors. ASCO, 2017.
7. Diab A, Hurwitz ME, Tannir N, Bernatchez C, Haymaker C, Bentebibel SE, Curti BD, Wong MK, Gergel I, Tagliaferri M, Zalevsky J. 1212TiPPIVOT-02: A phase 1/2, open-label, multicenter, dose escalation and dose expansion study of NKTR-214 and nivolumab in patients with select, locally advanced or metastatic solid tumor malignancies. Ann Oncol 28. suppl(5), 2017.
8. Wong MK, Morse M, McDermott DF, Clark J, Kaufman H, Daniels GA, Dutcher JP, Perritt JC, Hua H, Rao T.. Update on the overall survival of patients with metastatic melanoma treated with immune checkpoint blockade following initial treatment with HD IL-2. J Clin Oncol 34, 2016.
9. Clark J, McDermott DF, Dutcher JP, Wong MK, Kaufman H, Daniels GA, Morse M, Perritt JC, Hua H, Rao T.. Extension of overall survival in patients with metastatic renal cell carcinoma who received HD IL-2 followed by targeted therapy and/or immune checkpoint blockade from the PROCLAIM registry. J Clin Oncol 34, 2016.
10. Wong MK. Overall Survival of Metastatic Melanoma (mM) Treated with High Dose IL-2 (HD IL-2) Followed by Anti-CTLA4 (IPI) and/or Anti-PD-1/PD-L1 (aPD1) Therapy: Analysis of the Prospective Cohort of the PROCLAIM National Registry. ASCO, 2015.
11. Wong MK, Daniels GA, Kaufman HL, McDermott DF, Morse MA, Aung S, Lowder JN. High dose interleukin-2 registry, PROCLAIM™; higher center-specific IL-2 dose density correlates with higher response rates. Journal of Immunotherapy of Cancer 1(1):67, 2013.
12. Wong MK, Huang R-Y, Gray A. Targeting Melanoma Fibroblast Growth Factor (FGF) Secretion Through S100 Inhibits FGF-1 but Not FGF-2. Society for Melanoma Research, 2012.
13. Wong MK, Kaufman H, Morse M, McDermott DF, Lowder JN. The Transient Nature of Significant Toxicities Associated with High Dose Interleukin-2 (HD IL-2): Preliminary Data from the PROCLAIM™ Study. Society for Immunotherapy of Cancer, 2012.
14. Kaufman H, McDermott D, Morse M, Lowder J, Wong MK. THE PROCLAIM (PROLEUKIN® Observational Study to Evaluate Treatment Patterns and Clinical Response to Malignancy) Study: The Response Rates for High Dose Interleukin-2 (HD IL-2) Therapy. Society for Immunotherapy of Cancer, 2012.
15. Spencer SD, Figg WD, Rosen LS, Gordon MS, Hurwitz H, Wong MK, Goldman JW, Mendelson DS, Adams BJ, Alvarez D, Seon BK, Theuer CP, Leigh BR. Dose-specific clearance of TRC105 (anti-CD105 antibody) in advanced solid tumor patients. ASCO, 2012.
16. Yang H, Wong MK, J. E. Signorovitch JE, Wang X, Liu Z, Liu NS, Qi Z, George DJ. Overall and progression-free survival with everolimus, temsirolimus, or sorafenib as second targeted therapies for metastatic renal cell carcinoma: A retrospective U.S. chart review. ASCO, 2012.
17. Wong MK, Mohamed AF, Hauber AB, Yang J, Liu Z, Rogerio JW, Garay CA. Selecting renal cell carcinoma therapy: Ranking of patient perspective on toxicities. ASCO, 2012.
18. Huang R-Y, Odunsi K, Wong MKK. Identification of factors secreted by melanoma exhibiting propensity for lung metastases. Proceedings AACR, 2011.
19. Carvajal R D, Wong MK, Thompson J A, Gordon MS, Lewis KD, Pavlick AC, Wolchok JD, Fox E, Schwartz JD, Bedikian AY. A phase II randomized study of ramucirumab (IMC-1121B) with or without dacarbazine (DTIC) in patients (pts) with metastatic melanoma (MM). ASCO Annual Meeting 28(15):8519, 2010.
20. Logan T, Amin A, Cohen V, Wong MKK, Master A, Monesmith T, Healey D, Jain R, Plessinger D, Nicolette CA.. A Phase 1/2 Study of AGS-003, a personalized immunotherapeutic evaluated in newly diagnosed metastatic renal cell carcinoma subjects. ASCO, 2010.
21. Huang R-Y, Bowers D, Wong MK. Amlexanox inhibits FGF-mediated paracrine and autocrine activity of tumor-derived melanoma cell lines and cell strains. AACR, 2010.
22. Huang R-Y, Wong MK. Amlexanox (2-Amino-7-isopropyl-5-oxo-5H-(1) benzopyrant (2,3-b) pyridine-3-carboxylic acid) inhibits acidic fibroblast growth factor release from human melanoma cells. Proceedings AACR, 2009.
23. Chadha MK, Tian L, Mashtare T, Payne V, Silliman C, Levine E, Wong MK, Johnson C, Trump DL. Phase II trial of weekly intravenous 1,25 dihydroxy cholecaliferol in combination with dexamathasone for androgen independent prostate cancer. J Clin Oncol 26, 2008.
24. Yap JC, Kulkarni S, Fernando S, Wong MK. Primary angiosarcoma of the breast: Pattern of presentation, surgery, radiation, and survival. J Clin Oncol 26(15S):747s, 2008.
25. Wong MK, Henry DO, Mavis CK, Chen S, Reczek R. Interaction of sunitinib and paclitaxel on inhibition of human Angiosarcomas. J Clin Oncol 26(15S):637s, 2008.
26. Reczek PR, Henry DO, Wong MK. All-trans-retinoic acid (ATRA) induces cell death in human liposarcoma primary cell cultures. Proceedings AACR 2008, 2008.
27. Mavis C, Henry D, Chen S-C, Smiley S, Wong MKK. Low molecular weight heparin (LMWH) inhibition of tumor growth through the sequestion of angiogenic cytokines. Proceedings AACR 2008, 2008.
28. Chen S-C, Henry D, Wong MKK. Intravesical PAI-1 modifies the bladder tumor microenvironment and inhibits tumor invasion and angiogenesis. Proceedings AACR 2008, 2008.
29. Chen S-C, Henry D, Wong MK. Intravesical PAI-1 modifies the bladder tumor microenvironment and inhibits tumor invasion and angiogenesis. Proceedings AACR, 2008.
30. Ravi V, Kim S, Dim D, Hicks, D, Aggarwal C, Hostetter G, Cheney RT, Bitter M, Trump DL, Wong MK. Identification of therapeutic targets in angiosarcoma. J Clin Oncol 25(18S), 2007.
31. Dim D, Ravi V, Tan J, Hicks D, Wong M. The actin-bundling motility protein fascin and vascular endothelial growth factor (VEGF) are universally over-expressed in human angiosarcoma. J Clin Oncol 25(18S), 2007.
32. Henry DO, Chen S-C, Gupta S, Aggarwal C, Funnell JR, Wong MK. Arg-Arg-Leu peptide-targeted near infrared imaging of experimental prostate tumors in vivo. AACR, 2007.
33. Chen S-C, Henry DO, Tan J, Hicks DG, Wong MK. Endogenous PAI-1 expression inhibits experimental prostate tumors through endothelial apoptosis. AACR, 2007.
34. Ravi V, Henry D, Dim DC, Chen S-C, Aggarwal C, Hicks DG, Cheney RT, Wong MK. Chemoresistant malignant human endothelial cells overexpress angiogenesis and apoptosis genes. AACR, 2007.
35. Chen S-C, Henry DO, Gupta S, Tan J, Hicks DG, Wong MK. Intravesical PAI-1 inhibits bladder tumor progression by modifying the tumor microenvironment and inhibiting angiogenesis. AACR, 2007.
36. Pande AU, Lombardo JC, Fakih M, Wong MK, Iyer RV, Kuvshinoff BW, Javle MM.. Bevacizumab (BV) induced hypertension (HT): a manageable toxicity. J Clin Oncol 24(18S), 2006.
37. Ravi V, Henry D, Chen S, Wong MK. The mechanism of human angiosarcoma drug resistance. ASCO Annual Meeting Proceedings Part I. J Clin Oncol 24(18S (June 20 Supplement)), 2006.
38. Smiley SL, Henry DO, Wong MK. The mechanism of low molecular weight heparin (LMWH) inhibition of tumor growth. ASCO Annual Meeting Proceedings Part I. J Clin Oncol 24(18S (June 20 Supplement)), 2006.
39. Henry DO, Chen SC, Wong MK. Targeted molecular imaging of prostate cancer using tumor endothelium homing Arg-Arg-Leu peptides. ASCO Annual Meeting Proceedings Part I. J Clin Oncol 24(18S (June 20 Supplement)), 2006.
40. Chen SC, Henry DO, Wong MK. The biologic therapy of prostate cancer using plasminogen activator inhibitor-1 (PAI-1). ASCO Annual Meeting Proceedings Part I. J Clin Oncol 24(18S (June 20 Supplement)), 2006.
41. Chung I, Flynn G, Yu W, Wong MK, Johnson CS, Trump DL.. The in vitro and in vivo effect of 1,25-dihydroxycholecalciferol (calcitriol) on tumor-derived endothelial cell (TDEC) and matrigel-derived endothelial cell (MDEC). AACR, 2005.
42. Smiley SL, Henry DO, Chen BA S-C, Wong MKK. Heparins inhibit tumor angiogenesis by sequestering fibroblast growth factor (FGF) from tumor vascular endothelial cells. Blood 106, 2005.
43. Knox JJ, Ornstein D, Rathmell KW, Wong MKK, Jewett M, Corcos J, Finke LH, Miesowicz F, Nicolette CA, Batist G.. A phase I/II study of vaccination with autologous dendritic cells (DCs) transfected with autologous amplified tumor-derived mRNA in patients with stage IV renal cell carcinoma (RCC). J Clin Oncol 23:4712, 2005.
44. Chen S-C, Henry DO, Wong MK. Endogenous Plasminogen Activator Inhibitor-1 (PAI-1) Induces Tumor Regression by Vascular Collapse. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, 2005.
45. Chen S, Henry D, Tran S, Odoux C, Lawrence D, Wong MK. Plasminogen Activator Inhibitor – 1 (PAI-1) induces the regression of established bladder tumors. AACR, 2004.
46. Odoux CF, Albers A, Watkins S C, Wong MK, Whiteside TL.. Autocrine secretion of angiogenic factors and CCR7 expression by dendritic cells determine their migration. AACR, 2004.
47. Matin K, Ramanathan RK, Jacobs SA, Wong MK, Earle M. Evans T, Troetschel M, Ferri W, Frienland D, Wieand S.. Phase I/II study of trimetrexate (TMTX) and capecitabine (CAP) as second and third-line therapy in patients with advanced colorectal cancer (CRC). J Clin Oncol 22, 2004.
48. Wong MK, Modzelewski RA, Weller G, Villanueva FS, Henry D, Kirk JS, Brown CK, Wagner WR.. Ultrasound contrast visualization of tumor vasculature in vivo by targeted microbubbles. J Clin Oncol(22), 2004.
49. Odoux CF, Watkins SC, Wong MKK. Dendritic cells activate blood endothelial cell proliferation in vivo through basic FGF. AACR, 2003.
50. Midha R, Munro CA, Dalton PD, Wong MKK, Tator CH, Shoichet MS.. Novel biocompatible tube enhanced with growth factors supports peripheral nerve regeneration. Journal of Recontructive Microsurgery 18(7):629, 2002.
51. Huang X, Yi H, Wong MK, Laird AD, Wolf SF, Gorelik E.. Combined antiangiogenic and immune therapy of the established murine-4T1 breast tumor. AACR, 2002.
52. Odoux C, Albers A, Wong MK. Augmenting apoptosis in Paclitaxel-treated Human Non-Small-Cell Lung Cancer using TRAIL, FasL and a blocking anti-DR5 antibody. AACR 43: #3507, 2002.
53. Zamboni WC, Jung LL, Egorin MJ, Jin R, Wong MKK, Fakih M, Belani CP, Potter DM, Tauch JS, Walko CW, Strychor S, Sun S-L, Trump DL, Ramanathan RK.. Phase I studies of intermittently administered 9-nitrocamptothecin (9NC): relationship between daily dose and toxicity. ASCO, 2002.
54. Trump DL, Egorin MJ, Ramesh R, Capozzoli MJ, Polakowski S, Wong M, Fakih M, Stoller R, Jacobs S, Brufsky A, Mason-Liddil N, Kopit J, Bello A, Gupta E, Ogan M, Zeng J, LaCreta F, Hansel S, Perrone R, Rose W, R Tubertini, Palme T, Griffin T, Malik R.. A new oral taxane (BMS-275183): phase I trial with evaluation of pharmacokinetics, pharmacodynamics and bioavailability. ASCO, 2002.
55. Ramanathan R K, Jacobs S A, Wong MK, Earle M, Evans T, Troetschel M, Ferri W, Friedland D, Pinkerton R, Volkin R, Wieand S.. Phase I/II study of trimetrexate (TMTX) and capecitabine (CAP) as second and third line therapy in patients with advanced colorectal cancers (CRC). ASCO, 2002.
56. Levy M, Wong MK. Incubation with hepatocellular cultures enables SelCID to inhibit the growth of human renal cell carcinoma cells in vitro. ASCO, 2002.
57. Weller GER, Villanueva FS, Wong MK, Modzelewski RA, Klibanov AL, Wagner WR. Ultrasound contrast microbubbles targeted to tumor angiogenesis specifically bind tumor-derived endothelial cells. Proceedings of the Second Joint EMBS-BMES Conference 4.3.10.2:897-98, 2002.
58. Midha R, Shoichet MS, Dalton PD, Cao X, Munro CA, Noble J, Wong M. Tissue engineered alternatives to nerve transplantation for repair of peripheral nervous system injuries. AANS, 2001.
59. Odoux C, Albers A, Lotze MT, Wong MKK. Regulation of proangiogenic factor secretion by human dendritic cells. AACR, 2001.
60. Laman A, Modzelewski R, Brown CK, Wong MKK. Peptide ++O motifs derived from peptide display panning of cultured tumor endothelium possess the ability to bind to tumor vasculature in vivo. ASCO, 2001.
61. Odoux C, Albers A, Okada H, Gambotto A, Wong MKK. Dendritic cells produce angiogenic factors and are associated with angiogenic blood vessels in vivo. ASCO, 2001.
62. Grainne A. McMahon GA, Petitclerc E, Stefansson S, Smith E, Wong MKK, Westrick RJ, Ginsburg D, Brooks PC, Lawrence DA.. Regulation of Tumor Growth and Angiogenesis by Plasminogen Activator Inhibitor-1. Plasminogen Meeting, 2001.
63. Midha R, Dalton PD, Munro CA, Wong MK, Shoichet MS. Improved regeneration with a novel biocompatible tube enhanced with neurotrophic factors. CNS 51st Annual Meeting, San Diego CA. Awarded 2nd place. September 29-October 4, 2001.
64. Modzelewski RA, Weller GE, Wong MK, Brown CK, Lu E, Klibanov AL, Wagner WR, Villanueva FS.. Targeted tumor imaging with ultrasound in tumor-bearing mice by means of a tumor endothelium-specific binding peptide conjugated to perfluorobutane microbubbles. AACR, 2001.
65. Wong MK, Tran S., McMahon G, Stefansson S., Lawrence D.. Plasminogen Activator Inhibitor –1 (PAI-1) inhibits fibroblast growth factor mediated (FGF) tumor growth and angiogenesis in vivo. AACR, 2000.
66. Wong MK, McMahon GA, Stefansson S, Petitclerc E, Smith E, Tran S, Brooks PC, Lawrence DA.. Inhibition of Angiogenesis and Tumor Growth In Vivo By Plasminogen Activator Inhibitor-1 (PAI-1): Evidence For Both A Proteinase Dependent and A Proteinase Independent Pathway. ASCO, 2000.
67. Tran S, Dickson G, Kim Y, Logan T, Wong M. Human renal cell carcinoma cell lines produce angiogenic-active fibroblast growth factor-1 (FGF-1) and induce heparin-dependent growth of human endothelial cells. ASCO, 2000.
68. Dickson G, Tran S, Kim Y, Logan T, Wong MKK. Human renal cell carcinoma cells lines secrete Fibroblast Growth Factor (FGF) and stimulate vascular endothelial cell growth. AACR – Molecular Targets and Cancer Therapeutics, 1999.
69. Brown CK, Modzelewski R, Johnson C, Wong MKK. A novel approach for the identification of unique tumor vascular binding peptides using E. coli peptide display library. SSO, 1999.
70. Devinny J, Slee A, Winkles J, Kerr J, Wong MKK. A novel in vivo model system to study the biology and gene expression of fibroblast growth factor (FGF) induced angiogenesis. AACR, 1999.
71. Yepes M, Wong MKK, Cohen S.. Delayed administration of intravenous pure recombinant acidic fibroblast growth factor decreases size of cortical injury in an animal model of focal cerebral ischemia/reperfusion. Stroke, 1999.
72. Shoichet M, Midha R, Xudong C, Noble J, Munro C, Wong M. Investigating a new entubulation strategy to overcome peripheral nerve injury. Bioengineering, 1999.
73. Prudovsky I, Wong MK, Booth C, Liaw L, Maciag T.. Jagged-1 regulates the formation of matrix-dependent cord-like structures in NIH3T3 cells. Molecular Biology and Biochemistry, 1999.

Book Chapters

1. Smiley S, Wong MK, Mousa SA. Methods for monitoring of the anti-angiogenic activity of agents in patients: novel trial design. In: Angiogenesis Assays, A Critical Appraisal of Current Techniques. John Wiley & Sons, Ltd: Sussex, England, 341-355, 2006.
2. Gotlieb AI, Wong MKK. In: Atherosclerosis: Activation of the injured vessel wall. In: Cardiac Pathology. F. A. Davies Co: Philadelphia, 3-21, 1988.

Books (edited and written)

1. Gotlieb AL, Wong MKK. Current Concepts on the Role of the Endothelial Cytoskeleton in Endothelial Integrity, Repair and Dysfunction. CRC Press: Boca Raton, 81-101, 1988.

Letters to the Editor

1. Wong MK. Perspective on “Breslow thickness, Clark level, ulceration predict sentinel lymph node metastasis in thin melanomas”. HemOnc Today, 2013.
2. Roosta N, Wong MK, Woodley DT. Utilizing hairdressers for early detection of head and neck melanoma: An untapped resource. J Am Acad Dermatol 66: 687-88, 2012.
3. Wong MK. Selecting Appropriate Pharmacologic Treatment in Renal Cell Carcinoma: Considerations for Managed Care Decision Makers. Managed Care Oncology – Drug Therapy Reviews, 2012.
4. Wong MK. Expert Point of View: Dual BRAF and MEK Inhibition Is Active in Advanced Melanoma. The ASCO Post (as quoted by Caroline Helwick) 3, 2012.